A late CenterWatch (Boston, MA) stu...

A late CenterWatch (Boston, MA) study, published in the October issue of CenterWatch's monthly newsletter compass 8 Issue 10, finds that the incidence of death attributed to investigational treatments, during the two government and industry-sponsored clinical trials, is rare. The reflection also finds that one adverse end per research subject is typically reported in succession new drug applications approved at the FDA.

In September